Compare XMTR & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMTR | LENZ |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | 42 |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 551.3M |
| IPO Year | 2021 | 2021 |
| Metric | XMTR | LENZ |
|---|---|---|
| Price | $64.71 | $17.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $53.80 | ★ $56.25 |
| AVG Volume (30 Days) | 714.9K | ★ 1.2M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $642,780,000.00 | $17,500,000.00 |
| Revenue This Year | $26.71 | N/A |
| Revenue Next Year | $20.19 | $204.72 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.40 | N/A |
| 52 Week Low | $18.59 | $15.70 |
| 52 Week High | $69.26 | $50.40 |
| Indicator | XMTR | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 28.67 |
| Support Level | $58.51 | $16.30 |
| Resistance Level | $64.98 | $18.47 |
| Average True Range (ATR) | 3.40 | 2.07 |
| MACD | 0.27 | -0.67 |
| Stochastic Oscillator | 96.25 | 14.41 |
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.